pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
sniff results

“Keytruda”

170 total hits · 4 drugs · 0 companies · 0 diseases · 131 catalysts · 35 news

Drugs(4)

expand →
KEYTRUDA
KEYTRUDA · PEMBROLIZUMAB
Marketed
pembrolizumab
Keytruda · pembrolizumab
Merkel Cell Carcinoma
KEYTRUDA QLEX
KEYTRUDA QLEX · PEMBROLIZUMAB
Marketed
(berahyaluronidase alfa + pembrolizumab)
Keytruda Qlex · (berahyaluronidase alfa-pmph + pembrolizumab)
Muscle Invasive Bladder Cancer (MIBC)

🐶 Companies(0)

expand →
no companies matched

Catalysts(131)

expand →
view all 131 catalyst results →

News(35)

expand →
  • Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms↗
    On its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertensi…
    biospace · 1d ago
  • Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins↗
    Even as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial expansions over near-term margin growth, hoping to strengthen its long-term…
    fiercebiotech · 1d ago
  • Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3↗
    Capping off a busy few days in Spain, Genmab reported results from the first interim analysis of a phase 3 trial showing that adding its bispecific antibody petosemtamab to Merck & Co.'s Keytruda c…
    fiercebiotech
· 2d ago
  • #ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons↗
    MADRID — Akeso on Sunday spelled out just how much its Summit Therapeutics-partnered PD-1xVEGF bispecific improved survival in a late-stage, China-only biliary tract cancer study, in one of its ear…
    endpoints · 4d ago
  • #ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer↗
    MADRID — It's been estimated that almost 40,000 delegates will be attending this year's ESMO congress over five days in Madrid. And on Saturday, they have new data to review from AstraZeneca, Eli L…
    endpoints · 6d ago
  • ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak↗
    A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ expectations for recurrence-free survival, leaving questions as to its applic…
    biospace · 8d ago
  • Moderna, Merck shares fall on eagerly anticipated cancer vaccine results↗
    A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reacti…
    biopharma dive · 8d ago
  • Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success↗
    Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.
    stat · 15d ago
  • view all 35 news results →
    Jan 31, 2028
    phase readout
    in 1y
    Phase 2 primary completion: BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
    →
    Apr 6, 2026
    approval
    7mo ago
    KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
    (berahyaluronidase alfa + pembrolizumab)
    →
    Apr 6, 2026
    approval
    7mo ago
    KEYTRUDA (PEMBROLIZUMAB) — FDA approval
    pembrolizumab
    →
    Feb 10, 2026
    approval
    9mo ago
    KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
    (berahyaluronidase alfa + pembrolizumab)
    →
    Feb 10, 2026
    approval
    9mo ago
    KEYTRUDA (PEMBROLIZUMAB) — FDA approval
    pembrolizumab
    →
    Nov 21, 2025
    approval
    11mo ago
    KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
    (berahyaluronidase alfa + pembrolizumab)
    →
    Nov 21, 2025
    approval
    11mo ago
    KEYTRUDA (PEMBROLIZUMAB) — FDA approval
    pembrolizumab
    →
    Sep 19, 2025
    approval
    1y ago
    KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
    (berahyaluronidase alfa + pembrolizumab)
    →